摘要
目的:探讨不同静脉溶栓方案在治疗急性缺血性脑卒中(AIS)的效果。方法:选择2018年1月至2020年1月就诊的82例AIS患者作为研究对象,采用随机数字表法分为两组,每组41例。观察组给予重组人组织型纤溶酶原激活物(rt-PA)静脉溶栓及抗血小板药物治疗,对照组给予尿激酶(UK)静脉溶栓及抗血小板药物治疗,均持续治疗7 d。观察、分析两组的神经功能、溶栓后血管再通及安全性。结果:治疗7 d后,观察组美国国立卫生研究院卒中量表(NIHSS)评分低于对照组,血管再通情况优于对照组(P<0.05)。观察组不良事件发生率4.88%,低于对照组24.39%(P<0.05)。结论:Rt-PA静脉溶栓治疗AIS的效果优于UK静脉溶栓。
Objective:To investigate the effects of different intravenous thrombolysis schemes in the treatment of acute ischemic stroke(AIS).Methods:A total of 82 AIS patients admitted to our hospital from January 2018 to January 2020 were selected as the research objects,and were randomized into two groups,with 41 cases in each group.The observation group were treated with intravenous thrombolysis of recombinant human tissue-type plasminogen activator(rt-PA)and antiplatelet drugs,while the control group were treated with intravenous thrombolysis of urokinase(UK)and antiplatelet drugs,the treatment for both groups lasted for 7 d.Neurologic function and safety of thrombolytic vascular recanalization of patients were compared between both groups.Results:After 7 d of treatment,the NIHSS score of the observation group was lower than that of the control group,and the vascular recanalization of the observation group was better than that of the control group(P<0.05).The incidence of adverse events in the observation group was lower than that of the control group(P<0.05).Conclusion:Recombinant human tissue-type plasminogen activator(rt-PA)is more effective than urokinase(UK)in intravenous thrombolysis for patients with acute ischemic stroke(AIS).
作者
陈秀敏
CHEN Xiumin(Dept.of Neurology,the People’s Hospital of Zhecheng County,Zhecheng 476200,China)
出处
《华夏医学》
CAS
2021年第1期124-127,共4页
Acta Medicinae Sinica
